Goldman Sachs Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

March 8, 2024 7:00 AM EST

- PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints

- Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated

- Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Community to Share Topline Data; Amylyx Will Share Plans for RELYVRIO/ALBRIOZA in ALS Which May Include Voluntarily Withdrawing RELYVRIO/ALBRIOZA From the Market

- At This Time, RELYVRIO/ALBRIOZA Will Continue to be Available for People Living With ALS; Amylyx Has... More

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX

March 7, 2024 5:40 PM EST

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, both dates inclusive (the Class Period), of the important April 9, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Amylyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee... More

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

March 7, 2024 9:45 AM EST

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (Amylyx or the Company) (NASDAQ: AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in... More

DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline

March 7, 2024 7:30 AM EST

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Do you, or did you, own securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)?
Did you purchase your securities between November 11, 2022 and November 8, 2023, inclusive?
Did you lose money in your investment in Amylyx Pharmaceuticals, Inc.?
Do you want to discuss your rights?... More